The successful translation of gene therapy for clinical application will require the assessment of transgene activity as a measure of the biological function of a therapeutic transgene. Although current imaging permits the noninvasive detection of transgene expression, the critical need for quantitative imaging of the action of the expressed transgene has not been met. In vivo magnetic resonance spectroscopic imaging (MRSI) was applied to quantitatively delineate both the concentration and activity of a cytosine deaminase-uracil phosphoribosyltransferase (CD-UPRT) fusion enzyme expressed from a transgene. MRSI enabled the generation of anatomically accurate maps of the intratumoral heterogeneity in fusion enzyme activity. We observed an excellent association between the CD-UPRT concentration and activity and the percentage of CD-UPRT + cells. Moreover, the regional levels of UPRT activity, as measured by imaging, correlated well with the biological affect of the enzyme. This study presents a translational imaging paradigm for precise, in vivo measurements of transgene activity with potential applications in both preclinical and clinical settings. [Cancer Res 2008;68(8):2878-84] 
Introduction
The pharmacokinetic and pharmacodynamic properties of a drug determine its therapeutic efficacy in vivo (1) . This association holds true for all conventional drugs and suggests that the activity of novel therapeutic strategies, including gene therapy, must be thoroughly characterized to achieve therapeutic effect (2) . In the excitement to introduce gene therapy for clinical trial, the quantitative characterization of transgene activity has been underemphasized (3, 4) . The inability to translate the successes of preclinical gene therapy studies into clinical treatments has underscored this deficiency in quantitative data (5) . We show quantitative in vivo magnetic resonance (MR) spectroscopic imaging (MRSI) of the regional activity and concentration of an exogenous enzyme expressed from a therapeutic transgene. We further establish that MRSI measurements of regional transgene activity can provide an effective index of the biological function of this enzyme. The ability of MRSI to facilitate the in vivo assessment of transgene activity suggests a potential role for this technique in optimizing the implementation of gene therapy.
To date, noninvasive imaging approaches used to monitor gene therapy strategies have primarily focused on semiquantitative assessments of transgene expression (6) (7) (8) (9) (10) (11) . In contrast, the delineation of the regional activity of a transgene is expected to enable the functional evaluation of gene therapy. Transgene activity can be assessed through serial, quantitative, and noninvasive measurements of both the substrate specific for the transgene and its resultant metabolite(s). For example, the cytosine deaminase-uracil phosphoribosyltransferase (CD-UPRT) fusion enzyme metabolizes 5-fluorouracil (5-FU) and 5-fluorocytosine (5-FC) to discernible anabolites (refs. 12, 13; Fig. 1 ). MRSI is well suited for this application as it allows the absolute quantitation of transgene specific substrates and metabolites with spatial encoding that provides the opportunity to detect local variations in the target tissue (14, 15) . These substrates and metabolites may be distinguished in the acquired images based on their relative chemical shifts. In enabling the absolute quantitation of these resonances, MRSI provides the unique potential to characterize and to quantify transgene activity spatially and noninvasively in absolute terms.
Materials and Methods
CD-UPRT-expressing tumors. Walker 256 cells were grown in minimal essential medium supplemented with 10% FCS. Cells transduced with a SFG retroviral vector (16) coding for CD-UPRT and neomycin resistance ( Supplementary Fig. S3 ) were selected in the presence of 500 Ag/mL geneticin (Invitrogen) and then a robustly CD-UPRT-expressing clone (validated through cellular accumulation of [ 3 H]uracil) was propagated in antibiotic-containing medium. All tumors were inoculated by s.c. injection of 2 Â 10 6 W256 cells (wild-type or transduced) into the right flank of 5-to 6-wk-old male nude mice (nu/nu, National Cancer Institute). CD-UPRT gene expression was detected in tumors by immunohistochemistry as long as 7 wk after inoculation. Transplanted tumors were implanted under general anesthesia (ketamine/xylazine) and wound closure was achieved using a topical tissue adhesive (Nexaband Liquid, Abbott Animal Health). Tumor volumes and doubling times were determined as described previously (17) . To assay transgene expression in tumor tissue, Western blotting and immunohistochemical staining were performed as recommended by the manufacturer using a sheep anti-yCD polyclonal antibody (Biotrend Chemicals, Inc.). The detection of apoptosis in tumor sections was achieved by immunohistochemical staining using the cleaved caspase-3 primary antibody according to the manufacturer's instructions (Cell Signaling Technology). Regional apoptosis was quantitated using MetaMorph software (Universal Imaging Corp.). For this purpose, regions of interest (ROI) were prescribed onto contiguous tumor sections (10 Am spacing) stained for cytosine deaminase gene expression. These ROI were overlaid onto sections stained for caspase-3. Apoptotic indices are reported as the average number of cells staining positively for caspase-3 per square millimeter.
Radionuclide uptake assay. Accumulation assays using H]fluorouracil (12 mCi/mmol) and [2- 14 C]fluorocytosine (53 mCi/mmol; Moravek Biochemicals) were done as described previously (18) and expressed as the cell to medium radiotracer accumulation ratio (mL/g; ref. 19 ).
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F-MRS. Mice were prepared and positioned for the experiments as described previously (12) . Spectral variables included 700 signal averages, 1,024 data points, a 60j flip angle, a 1.7-s repetition time, and a 12-kHz spectral width. A microsphere containing a 150 mmol/L NaF (Sigma-Aldrich) aqueous solution doped with 15 mmol/L Magnevist (Berlex Laboratories, Inc.) and positioned adjacent to the center of the coil was used as an external reference for quantitation. The NaF spectral parameters included 700 averages, 1,024 data points, a 90j flip angle, a 600-ms repetition time, and a 12-kHz spectral width.
Spins were quantitated using the AMARES algorithm (20) . Cramer-Rao bounds (CRB) were used to estimate the achievable precision of this algorithm (21) . In accordance with the literature, considerations relevant to data acquired using the external reference technique were included in the analysis (22, 23) . Measured in vivo spin-lattice relaxation times of 5-FU and fluoronucleotides (FNuc) were used to correct the metabolite signal areas for partial saturation effects (12). The SITOOLS (24) package was used to process the images and to generate the parametric maps. CD-UPRT enzyme concentrations and activity were determined by scaling the estimated V max due solely to UPRT (V max,5FU
UPRT À V max,5FU wt ) by the ratio of the FNuc concentration in the relevant voxel to the FNuc concentration at the same time point in the modeled data. Corrections for intervoxel signal contamination were unnecessary for our voxel sizes (f3.0 mm Â 3.0 mm Â 5.0 mm) as described previously (25) and confirmed empirically (data not shown).
Pharmacokinetic modeling. A five-compartment pharmacokinetic model was developed to simultaneously fit 2 one-compartment and 2 two-compartment models including 5-FU in plasma, 5-FU in both tumor types, as well as FNuc in each tumor type ( Fig. 2A) . The model is based on certain assumptions: (a) first-order kinetics for the cellular transport of 5-FU; (b) the enzyme-mediated conversion of 5-FU into FNuc and the further anabolism of FNuc were saturable and followed Michaelis-Menten constraints; (c) a single composite rate equation for the anabolism of FNuc. Certain kinetic variables were assumed to be the same for both the CD-UPRT À and CD-UPRT + tumors, including (a) the rate constant describing the transport of 5-FU into (k 1 ) and out of (k 2 ) the tissue; (b) the conversion of FNuc into anabolites not measured by MRS (V max,5FU FNuc and K m,FNuc ); (c) the half saturation concentration for the 5-FU to FNuc reaction (K m,5FU ). The values for V max,5FU wt and V max,5FU UPRT were allowed to vary independently. Each 19 F-MRS tissue metabolite measurement was converted into a weighted average over five tumors using the inverse of the uncertainty as the weight. The uncertainty in each measurement was estimated to be at its CRB. The inverse of these uncertainties was later used during the fitting process to weight each data point. Metabolite concentrations that were below the detection limit were assumed to be at a median concentration of 200 Amol/L and were assigned an uncertainty of 600 Amol/L based on empirically determined thresholds (400 Amol/L) consistent with measured CRBs.
Liquid chromatography/mass spectrometry was used to measure plasma 5-FU concentrations drawn from non-tumor-bearing mice (n = 3 per time point) administered 150 mg/kg 5-FU. The resulting 5-FU plasma curve was used as a forcing function for the plasma 5-FU compartment. Each of the five compartments was associated with data from the 19 F-MRS-derived time series. A nonlinear fitting procedure was used to achieve the best weighted least-squares fit of each of the four tissue compartments to each of the four measured time series simultaneously. The half-saturation concentration for the UPRT-mediated reaction (K m,5FU ) was fixed at 25 Amol/L (26). Five of the remaining variables (k 1 , k 2 , V max,5FU wt , V max,5FU UPRT , and V max,5FU FNuc ) were allowed to vary during the iterative fitting procedure. Because of the potential that K m,FNuc would lack a clearly defined minimum, the fitting procedure was run repeatedly with K m,FNuc values ranging from 0.1 Amol/L to 1,680 mmol/L. Twenty-five fits were evaluated in total and the target function and variable values were noted (Supplementary Fig. S4A and B) . Solutions to the rate equations and the nonlinear fitting were done using MATLAB v5.3 (Mathworks) routines.
Statistical analysis. Mean values are reported as mean F SE. Radiotracer accumulation was analyzed using the paired two-tailed Student's t test. Apoptosis indices were analyzed using a one-way ANOVA.
Results
The CD-UPRT fusion enzyme was selected as a model transgene system for the imaging of transgene activity because of the versatility it offers with respect to MR-visible probes (Fig. 1) . We initially compared 5-FC and 5-FU as potential probes for the assessment of CD-UPRT activity. Radionuclide uptake studies using [ 14 Supplementary  Fig. S1 ). These data, which show the accumulation of radiotracer at an appreciably higher rate and to substantially higher levels for incubations of CD-UPRT + cells with [ 3 H]5-FU compared with [ 14 C]5-FC, suggest that 5-FU should provide better sensitivity and, relatedly, superior temporal and spatial resolution than 5-FC as an in vivo MR probe for CD-UPRT levels and activity.
In addition to an effective reporter-probe system, imaging transgene activity requires a pharmacokinetic model to characterize the function of the transgene in living tissue. Toward this end, we next fit absolute metabolite concentrations derived from Fig. S2 ) to a pharmacokinetic model describing the kinetics of 5-FU in CD-UPRT + and CD-UPRT À tumors ( Fig. 2A) . Fits of the 19 F-MRSderived metabolite concentrations to this model ( Fig. 2B and C) enabled the variables controlling the transport and metabolite conversions between the various compartments to be determined for wild-type and transduced tumors (Fig. 2D ). The measured substrate concentrations (5-FU) greatly exceeded the reported UPRT K m (25 Amol/L; ref. 26) such that the UPRT was producing FNuc at or near to its maximal rate. As shown in Fig. 2D , the maximum rate of 5-FU anabolism in CD-UPRT + tumors (V max,5FU UPRT ) was >3-fold larger than that associated with the activity of endogenous enzymes in CD-UPRT À tumors (V max,5FU wt ). The UPRT-specific V max,5FU (V max,5FU
UPRT À V max,5FU wt ) was determined to be 1.113 Akat; this represents the maximum enzymatic rate specific to UPRT and, as such, is also a direct measure of the CD-UPRT protein concentration. Moreover, because the pharmacokinetic model follows Michaelis-Menten (nonlinear) kinetics, this UPRT-specific rate can be used to determine the activity of the CD-UPRT fusion enzyme for any single time point measurement of FNuc concentration. This relationship allowed the application of the pharmacokinetic model to achieve quantitative images of transgene activity measuring regional CD-UPRT concentration and activity. Following the i.v. injection of 150 mg/kg (450 mg/m 2 ) 5-FU into mice bearing CD-UPRT + tumors, two-dimensional 19 F-MRS images were acquired. These images were overlaid onto corresponding twodimensional proton images to coregister the 19 F-MRSI spectra with ). The transport of 5-FU in and out of the cell was assumed to follow first-order kinetics, whereas enzyme-mediated conversions of 5-FU to FNuc and all subsequent anabolism of FNuc were assumed to be saturable and, therefore to follow Michaelis-Menten constraints. B and C pharmacokinetic analysis of 5-FU and its anabolites in CD-UPRT À and CD-UPRT + tumors respectively. 19 F-MRS-determined concentrations of 5-FU (5, -) and FNuc (o, ---) were fit to the pharmacokinetic model (A). The initial time points at which 5-FU (n) and FNuc (.) concentrations became subthreshold are indicated to represent the uncertainty that was associated with these measurements. D, the resulting rate constants and maximal conversion rates are shown.
tumor anatomy (Fig. 3) . Each voxel of the 19 F-MRS image shows the level of FNuc within a 0.045 cm 3 tumor volume with an in-plane resolution of 3.0 mm Â 3.0 mm. The homogeneous delivery of 5-FU was indicated by the uniform distribution of fluorinated anesthetic observed throughout the tumor by MRSI (resonance located 75 ppm from 5-FU; data not shown). The measured FNuc concentration within these voxels enabled the generation of parametric maps of regional UPRT activity (Fig. 3A) . In all but one of these tumors (n = 8), UPRT activity seemed to be homogeneous. In Fig. 3B, voxels I , II, and III show similar levels of UPRT activity (f0.841 Akat) whereas UPRT activity in voxel IV is undetectable despite the presence of significant amounts of substrate 5-FU. In addition to the detection of heterogeneous enzyme activity within CD-UPRT + tumors, Fig. 3C shows that 19 F-MRSI enabled the assessment of CD-UPRT concentrations and UPRT activity in mixed tumors constituted from equal parts wildtype and CD-UPRT-transduced W256 cells. As expected, the FNuc concentrations and the range of enzyme activity in mixed tumors is approximately half that of fully transduced tumors. This difference is further reflected in the decreased signal-to-noise ratio associated with the spectra in the mixed tumors compared with that in the fully transduced tumors.
Finally, we undertook experiments to investigate the relationship between MRSI-measured UPRT activity and the biological activity of this enzyme. For this purpose, we developed a mouse model in which sections of CD-UPRT + and CD-UPRT À tumors were transplanted side by side into the flanks of athymic nu/nu mice (n = 6). A representative example is shown in Fig. 4 . Quantitative
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F-MRS images of these cotransplanted tumors showed a discreet pattern of regional UPRT activity (Fig. 4A) . To correlate transgene activity, gene expression, and biological function, the acquired spectroscopic images were coregistered with tumor sections stained for CD-UPRT gene expression as well as caspase activity. As expected, tumor regions demonstrating UPRT activity by imaging correlated to those regions staining for CD-UPRT gene expression (Fig. 4B) . Moreover, as early as 6 hours following 5-FU therapy, a significant difference in FNuc-induced apoptosis was observed in tumor regions exhibiting UPRT activity and expression compared with regions showing neither (Fig. 4C-E) . Taken together, these data suggest that the imaging of transgene activity provides a relevant index of gene therapy.
Discussion
The studies presented here introduce a paradigm for the in vivo assessment of transgene activity through quantitative MRS imaging. The quantitation of in vivo metabolites in absolute units of concentration allowed the modeling of expressed transgene activity in absolute, SI coherent units of enzyme activity. In developing the pharmacokinetic model, we determined that a Figure 3 . In vivo imaging of transgene activity. 19 F-MRS images of FNuc (red arrows ) and associated parametric maps of regional CD-UPRT levels and activity within CD-UPRT + xenografts. Inset, the slice orientation of the acquired images.
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F-MRS-enabled images demonstrating homogeneous enzyme activity (A) to be distinguished from xenografts exhibiting regional heterogeneities in CD-UPRT activity (B). An area of deficient CD-UPRT activity is evident within voxel IV and is underscored by the presence of unmetabolized 5-FU (yellow arrow ).
19 F-MRSI was also able to discern CD-UPRT enzyme levels and activity in mixed xenografts grown from equal parts CD-UPRT + and CD-UPRT À cells (C ). Homogeneous CD-UPRT activity was seen; however, this activity is reduced compared with CD-UPRT + tumors (A).
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Michaelis-Menten analysis is required for single time point spectroscopic imaging of transgene activity (27) . Using this analysis, we achieved the first reported quantitative images of transgene action in absolute terms and we were able to discern regional heterogeneities in the activity of the CD-UPRT fusion enzyme. MRSI enabled unique insights into regional heterogeneity that would not be discernible by other noninvasive imaging modalities. This point is underscored by the presence of a 5-FU resonance and the noticeable absence of a FNuc resonance in voxel IV of Fig. 3B . Assessments of this tumor using positron emission tomography would be unfeasible because signals resulting from 5-FU and FNuc would be indistinguishable, leading to the false impression of homogenous enzyme activity. In addition, we found that CD-UPRT concentration and activity were proportional to the percentage of CD-UPRT + cells. Furthermore, regional levels of UPRT activity as measured by imaging correlated with metaboliteinduced apoptosis evincing that the noninvasive assessment of transgene activity can perhaps provide predictive insights into the therapeutic competency of a gene therapy system.
In this application, MRSI offers the potential for significant versatility as spectroscopic imaging of several MR-visible nuclei, including hydrogen, fluorine, phosphorus, and carbon (28), have been described. Transgene products that modify substrates containing these nuclei can potentially be monitored by MRSI reporter gene imaging. Several MRS reporter strategies have been developed, including creatine kinase, arginine kinase, and hgalactosidase (29) (30) (31) . These strategies are not limited to intracellular proteins; MRSI has also been used to show extracellular enzyme function in vivo (32) . This breadth of applications notwithstanding, several technical issues for the quantitative assessment of expressed transgenes by MRSI must be considered. The sensitivity of MRSI is inherently limited and sufficient metabolite concentrations must be sustained during image acquisition to achieve adequate spatial resolution. For example, the rapid anabolism of 5-FU by UPRT resulted in high concentrations of FNuc that were sustained for more than 5 hours in vivo. In contrast, the metabolism of 5-FC by CD-UPRT does not result in persistently elevated levels of fluorinated anabolites (13) , suggesting that 5-FC would be a less effective probe for MRSI of CD-UPRT (data not shown). The anabolite levels required to image CD-UPRT activity in vivo are intrinsically related to the administered dose of 5-FU as well as the level of transgene expression. The described Figure 4 . In vivo imaging of transgene activity provides an index of biological enzyme function. A, 19 F-MRS image and associated parametric map demonstrating circumscribed regions of CD-UPRT levels and activity within a CD-UPRT + /CD-UPRT À cotransplanted tumor xenograft at a digital resolution of 1.8 mm Â 1.8 mm. B, the regional distribution of UPRT activity closely parallels the expression pattern of the CD-UPRT transgene as determined by immunohistochemical staining. Apoptotic indices measured in a contiguous slice of tumor tissue through staining for cleaved capase-3 showed that regions with low, medium, and high apoptotic indices (C-E ) correlated well with transgene activity (13.2 F 2.9, 23.8 F 1.8, and 61.2 F 2.4 apoptotic cells/mm 2 , respectively, P < 0.0001).
experiments involved a bolus i. 6 CD-UPRT + cells at 4.7 T. The delineation of transgene activity holds significant implications for the optimization of gene therapy in oncology as well as other disciplines. The correlation of expressed transgene levels and activity with dosing schedules and/or routes of administration could be used to evaluate the efficacy of vector delivery. Similarly, the ability of MRSI to show differences in the activity of the expressed transgene could be applied to assess regional differences in vector distribution. Further, the accurate quantitation of tissue metabolites for the delineation of pharmacokinetic variables in absolute units could enable comparisons with conventional biochemical assays and facilitate the translation of in vitro data for in vivo application. For example, the in vitro 5-FU IC 50 Importantly, our approach could be applied to acquire these data in a clinical setting. The described MR techniques are feasible using existing technology. Clinical MRSI is routinely applied (35, 36) and quantitative MRSI of 5-FU pharmacokinetics in patients has been described previously (37) on available 1.5 T MR scanners. The current availability of higher field strength magnets for clinical studies (3-9 T) affords the opportunity for improved sensitivity in MRSI. Ongoing clinical trials of 5-FC-CD cancer gene therapy (38) suggest that MRSI monitoring of gene therapy could have immediate implications for the investigation of current strategies. Thus, MRSI offers the potential to gain new and essential insights into in vivo transgene activity in both preclinical and clinical settings.
